Chlormezanone

Summary

Chlormezanone (CHEMBL1200714) is an approved small-molecule anxiolytic drug (ATC M03BB72).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: M03BB72 (+2 more)
• Chemistry: 273.74 Da · C11H12ClNO3S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200714
Name	Chlormezanone
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	2717
ChEBI	CHEBI:3619
ATC	M03BB72, M03BB52, M03BB02
Molecular formula	C11H12ClNO3S
Molecular weight	273.74
InChIKey	WEQAYVWKMWHEJO-UHFFFAOYSA-N

SMILES: CN1C(S(=O)(=O)CCC1=O)C2=CC=C(C=C2)Cl

IUPAC name: 2-(4-chlorophenyl)-3-methyl-1,1-dioxo-1,3-thiazinan-4-one

ChEBI definition: A 1,3-thiazine that is 1,3-thiazinan-4-one S,S-dioxide in which a hydrogen at position 2 is substituted by a 4-chlorophenyl group and the hydrogen attached to the nitrogen is substituted by methyl. A non-benzodiazepine muscle relaxant, it was used in the management of anxiety and in the treatment of muscle spasms until being discontinued worldwide by its manufacturer in 1996, due to rare but serious cutaneous reactions.

Pharmacological roles (ChEBI): anxiolytic drug, muscle relaxant, antipsychotic agent.

Also known as: Chlormezanone, Clormezanona, Lyseen new, NSC-169108, Trancopal, SID26747112, SID26751725, SID50104419, SID85230949, CHLORMEZANONE, SID90340648, chlormezanone

Patent coverage: 631 distinct patent families (2,121 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Prelamin-A/C, Peripheral myelin protein 22, Thyroid hormone receptor beta, DNA repair nuclease/redox regulator APEX1.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 6 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
LMNA	5.25	Potency	5623	nM	CHEMBL_ACT_3650103

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).